The latest issue of Liver Internatioal (IF:4.4), the official journal of the International Society of Liver Diseases, published online a research paper on biologic therapy for liver cancer by Dr. Tao Li, deputy chief physician of Qilu Hospital, Shandong University. Malignant tumor cells are often accompanied by structural alterations of cell surface glycoproteins, and mannose expression tends to be elevated in malignant tumor cells. This study found that the expression of mannose on the surface of hepatocellular carcinoma cells was significantly higher than that of normal liver cells, and the biologic agent PA-MSHA, synthesized through biogenetic engineering, could specifically recognize and bind to mannose on the surface of hepatocellular carcinoma cells, inhibit the EGFR/Akt/IκBβ/NF-κB signaling pathway, thereby inhibiting the proliferation of hepatocellular carcinoma, inducing apoptosis and cell cycle arrest in hepatocellular carcinoma cells, and inhibit the invasive metastasis of hepatocellular carcinoma in vivo by suppressing the epithelial mesenchymal transition of hepatocellular carcinoma. This study uses hepatocellular carcinoma cell surface glycoprotein as a therapeutic target, which provides a new idea and scheme for the biological treatment of hepatocellular carcinoma and helps to improve the prognosis of hepatocellular carcinoma patients and reduce the recurrence and metastasis after surgery, and has positive clinical application value.